檢索結果 - Debashis Sarker

Refine Results
  1. 1
    Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

    Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics 由 Debra H. Josephs, Debashis Sarker

    出版 2015
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

    Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer 由 Debashis Sarker, Alison Reid, Timothy A. Yap, Johann S. de Bono

    出版 2009
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

    Improving the outcome of patients with castration-resistant prostate cancer through rational drug development 由 Gerhardt Attard, Debashis Sarker, Alison Reid, R. Molife, Chris Parker, Johann S. de Bono

    出版 2006
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials

    Effect of Patient Socioeconomic Status on Access to Early-Phase Cancer Trials 由 Aisyah Mohd Noor, Debashis Sarker, Suzanne Vizor, Blair Kp McLennan, Sarah Hunter, Aneta Suder, Henrik Møller, James Spicer, Sophie Papa

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study

    Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study 由 Sam Sollie, Dominique S. Michaud, Debashis Sarker, Sophia N. Karagiannis, Debra H. Josephs, Niklas Hammar, Aida Santaolalla, Göran Walldius, Hans Garmo, Lars Holmberg, Ingmar Jungner, Mieke Van Hemelrijck

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

    First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer 由 Christophe Massard, A. Ázaro, Jean‐Charles Soria, Ulrik Lassen, Christophe Le Tourneau, Debashis Sarker, Claire Smith, U. Ohnmacht, Gerard J. Oakley, Bharvin K.R. Patel, Eunice Yuen, Karim A. Benhadji, Jordi Rodón

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

    First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor 由 Ruth Plummer, Divyanshu Dua, Nicola Cresti, Yvette Drew, Peter Stephens, Marie L. Foegh, Steen Knudsen, Perminder S. Sachdev, Bipin Mistry, Vaishali Dixit, Sharon McGonigle, Nancy Hall, Mark Matijevic, Shannon McGrath, Debashis Sarker

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer 由 Rebecca Kristeleit, Ruth Plummer, Robert H. Jones, Louise Carter, Sarah P. Blagden, Debashis Sarker, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara Klencke, Mark Kowalski, Udai Banerji

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

    Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours 由 Nicholas C. Turner, Sandra J. Strauss, Debashis Sarker, Roopinder Gillmore, Amy A. Kirkwood, A. Hackshaw, Anthie Papadopoulou, J. Bell, Irfan Kayani, Christos Toumpanakis, Federica Grillo, A Mayer, Daniel Hochhauser, Richard H. J. Beǵent, Martyn Caplin, Tim Meyer

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

    A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors 由 Debashis Sarker, R. Molife, T. R. J. Evans, Maryon Hardie, Cheryl Marriott, Priska Butzberger-Zimmerli, Rosemary Morrison, Judith A. Fox, Carla Heise, Sharianne G. Louie, Natasha Aziz, F. Garzon, Glenn Michelson, Ian Judson, Dalal Jadayel, Edgar Braendle, Johann S. de Bono

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

    USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer 由 Jessica K. Nelson, May Zaw Thin, Theodore Evan, Steven Howell, Mary Wu, Bruna Almeida, Nathalie Legrave, Duco S. Koenis, Gabriela Koifman, Yoichiro Sugimoto, Miriam Llorián Sopeña, James I. MacRae, Emma Nye, Michael Howell, Ambrosius P. Snijders, Andreas Prachalias, Yoh Zen, Debashis Sarker, Axel Behrens

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets

    Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets 由 D. Britton, Yoh Zen, Alberto Quaglia, Stefan Selzer, Vikram Mitra, Christopher Lößner, Stephan Jung, Gitte Böhm, Peter Schmid, Petra Prefot, Claudia Hoehle, Saša Končarević, Julia M.W. Gee, Robert I. Nicholson, Malcolm Ward, Leandro Castellano, Justin Stebbing, Hans Dieter Zucht, Debashis Sarker, Nigel Heaton, Ian Pike

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

    The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanc... 由 Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, Sabine Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, Carla M.L. van Herpen

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib

    Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib 由 Masatoshi Kudo, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Thomas Yau, Ellen B. Gurary, Abby B. Siegel, Anran Wang, Ann‐Lii Cheng, Andrew X. Zhu

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2

    Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2 由 Hemant M. Kocher, Charlotte Ackerman, Garima Priyadarshini, Cheryl Lawrence, Nishtha Kotriwala, Ramona Georgescu, Rhiannon Roberts, Christine S. Hughes, Ahmet Imrali, Claude Chelala, Judith Dixon-Hughes, David K. Chang, Peter Sasieni, Pippa Corrie, Mairéad G. McNamara, Debashis Sarker, Fieke E. M. Froeling, Alan Christie, Roopinder Gillmore, Khurum Khan, David Propper

    出版 2025
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

    Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer 由 Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine S. Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David Propper

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

    First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors 由 Debashis Sarker, Joo Ern Ang, Richard D. Baird, Rebecca Kristeleit, Krunal Shah, Víctor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia G. Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial

    Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial 由 Gontran Verset, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stål, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann‐Lii Cheng, Sadahisa Ogasawara, Bruno Daniele, Stephen L. Chan, Jennifer J. Knox, Shukui Qin, Abby B. Siegel, Michael Chisamore, Ken Hatogai, Anran Wang, Richard S. Finn, Andrew X. Zhu

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells

    CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells 由 Rémi Samain, Óscar Maiques, Joanne Monger, Hoyin Lam, Juliana Candido, Samantha L. George, Nicola Ferrari, Leonie KohIhammer, Sophia Lunetto, A. Senra Varela, José L. Orgaz, F Vilardell, Jorge Juan Olsina Kissler, Xavier Matías‐Guiu, Debashis Sarker, Adrian Biddle, Frances R. Balkwill, Jim Eyles, Robert W. Wilkinson, Hemant M. Kocher, Fernando Calvo, Claire M. Wells, Victoria Sanz‐Moreno

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma

    Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma 由 Ghassan K. Abou‐Alfa, Shukui Qin, Baek‐Yeol Ryoo, Sheng‐Nan Lu, C-J. Yen, Yin‐Hsun Feng, Ho Yeong Lim, Francesco Izzo, M. Colombo, Debashis Sarker, Luigi Bolondi, Gina M. Vaccaro, William Proctor Harris, Z. Chen, Richard Hubner, Tim Meyer, Weijing Sun, James J. Harding, Ellen Hollywood, Jennifer Ma, Peter J. Wan, Michele Ly, John S. Bomalaski, A. E. Johnston, C.-C. Lin, Yee Chao, Liqun Chen

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: